Thalidomide, an antiangiogenic agent with clinical activity in cancer

Despite the teratogenic past of thalidomide, there is recent evidence indicating the drug’s efficacy in the management of various diseases from immune disorders to cancers. The history, pharmacodynamic and pharmacokinetic properties of thalidomide in the clinic are discussed in this review article....

Full description

Saved in:
Bibliographic Details
Published inBiomedicine & Pharmacotherapy Vol. 56; no. 4; pp. 194 - 199
Main Authors Ng, S.S.W., Brown, M., Figg, W.D.
Format Book Review Journal Article
LanguageEnglish
Published Paris Elsevier SAS 01.06.2002
Elsevier
Subjects
Angiogenesis Inhibitors - chemistry
Angiogenesis Inhibitors - pharmacokinetics
Angiogenesis Inhibitors - therapeutic use
Animals
Antineoplastic agents
bFGF
Biological and medical sciences
Chemotherapy
Clinical Trials as Topic - statistics & numerical data
HIV-infection
Humans
Medical sciences
Neoplasms - drug therapy
Neoplasms - metabolism
Neovascularization, Pathologic - drug therapy
Neovascularization, Pathologic - metabolism
Pharmacology. Drug treatments
Thalidomide
Thalidomide - chemistry
Thalidomide - pharmacokinetics
Thalidomide - therapeutic use
VEGF
HIV-infection
Thalidomide
VEGF
bFGF
Antineoplastic agent
Human
Pharmacokinetic pharmacodynamic relationship
Toxicity
Review
Malignant tumor
Long term
Biological activity
Immunomodulator
Chemotherapy
Treatment
Clinical trial
Antiangiogenic agent
Mechanism of action
Pharmacokinetics
Online AccessGet full text

Cover

More Information
Summary:Despite the teratogenic past of thalidomide, there is recent evidence indicating the drug’s efficacy in the management of various diseases from immune disorders to cancers. The history, pharmacodynamic and pharmacokinetic properties of thalidomide in the clinic are discussed in this review article.
ISSN:0753-3322
1950-6007
DOI:10.1016/S0753-3322(02)00177-4